This document discusses issues with reproducibility and open access in scientific research. It notes studies showing that over 50% of published studies cannot be repeated, and major pharmaceutical companies could only validate around 25% of preclinical studies. It argues that the current publishing system, dominated by for-profit publishers, boxes in academic knowledge and prioritizes profits over open access. The document advocates for cultural and technological changes like open access policies, altmetrics, and software for reproducible research to help make science more open.